Compugen Ltd Announces FDA Clearance for COM902
Today, Compugen Ltd, a clinical-stage cancer immunotherapy company and one of the pioneers of predictive target discovery declared that its investigational new drug (IND), COM902, has been approved by the US Food and Drug Administration for further trials and research. COM902 is an immuno-oncology therapeutic antibody targeting TIGIT that can be highly effective in the…